-The Times of India BHUBANESWAR: He zips around in a Toyota Fortuner but is listed as a below poverty line (BPL) beneficiary. Biju Janata Dal MLA Srinath Soren, from Udala in Mayurbhanj district, who declared his assets in 2009 that in no way qualify him for such benefits, nevertheless has his wife and two kids as well listed under BPL. The information was obtained through an RTI application. Soren, a first-term MLA,...

-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...

-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...

-The Business Standard Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up Though the India office here of Swiss pharma giant Novartis wore a gloomy look following the Supreme Court rejection of its Glivec patent application, Indian pharmaceutical companies and patients' associations are in celebration mood. D G Shah, secretary general, The Indian Pharmaceutical Alliance (IPA), comprising leading research-based Indian pharma companies, said,...

-The Hindu Union Commerce and Industry Minister Anand Sharma has termed "historic" the Supreme Court's rejection of Novartis' claim for patent for its anti-cancer drug Glivec. He said the Indian Patent Act was in conformity with its international obligations under the Trade Related Aspects of Intellectual Property Rights Agreement. "It is a historic judgment. It reaffirms the position of Indian law and, in particular, provisions of Section 3D, which mandates... a substantive...